Posted by Michael Wonder on 05 Sep 2024
Winrevair (sotatercept) is now authorised for use in Canada for adults with pulmonary arterial hypertension
4 September 2024 - Merck announced that Winrevair (sotatercept) is now authorised for use in Canada in combination with standard pulmonary arterial hypertension therapy, for the treatment of adults with World Health Organization Group 1 pulmonary arterial hypertension and functional class II or III.
Sotatercept is the first activin signaling inhibitor therapy for pulmonary arterial hypertension in Canada.
